Literature DB >> 7488572

Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease.

H Mietz1, K Heimann.   

Abstract

AIMS: This study aimed to evaluate both the mean time intervals between retinal disease and the development of proliferative vitreoretinopathy (PVR) and the time intervals at which recurrent PVR develops following various kinds of vitreoretinal disease and surgery.
METHODS: One hundred and thirty six consecutive cases of PVR that were seen and operated on between 1991 and 1994 were evaluated retrospectively. Intervals between onset of disease and PVR or recurrent PVR were noted. Conditions leading to PVR, surgical procedures, and the final anatomical and functional results were evaluated.
RESULTS: Before PVR was noted for the first time, an average of 1.06 vitreoretinal surgical procedures were performed (range 0 to 3). A mean of 1.99 surgeries were performed to control PVR or to reach an end stage where further surgery would have been unreasonable (range 0 to 5). The average (median) time interval between the onset of the retinal disease and PVR was 2.0 months (range 0.5 to 45 months). The median time intervals between surgery and recurrence for the second, third, or fourth times was also 2.0 months (range 0.5 to 34 months).
CONCLUSIONS: PVR starts earliest at 2 weeks after an event and subsequently quietens down within a maximum of 45 months after treatment (median 2 months). PVR may recur more than once but the time course of the disease is likely to be the same for each recurrence.

Entities:  

Mesh:

Year:  1995        PMID: 7488572      PMCID: PMC505285          DOI: 10.1136/bjo.79.10.874

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  Pathogenetic mechanisms in anterior proliferative vitreoretinopathy.

Authors:  P F Lopez; H E Grossniklaus; T M Aaberg; P Sternberg; A Capone; H M Lambert
Journal:  Am J Ophthalmol       Date:  1992-09-15       Impact factor: 5.258

Review 2.  Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration.

Authors:  P Wiedemann
Journal:  Surv Ophthalmol       Date:  1992 Mar-Apr       Impact factor: 6.048

3.  Idiopathic epiretinal membranes. Ultrastructural characteristics and clinicopathologic correlation.

Authors:  W E Smiddy; A M Maguire; W R Green; R G Michels; Z de la Cruz; C Enger; M Jaeger; T A Rice
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

4.  Massive periretinal proliferation: a logical approach to therapy.

Authors:  R Machemer
Journal:  Trans Am Ophthalmol Soc       Date:  1977

5.  Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells.

Authors:  B M Glaser; J Vidaurri-Leal; R G Michels; P A Campochiaro
Journal:  Ophthalmology       Date:  1993-04       Impact factor: 12.079

Review 6.  Traction retinal detachment. XLIX Edward Jackson Memorial Lecture.

Authors:  S J Ryan
Journal:  Am J Ophthalmol       Date:  1993-01       Impact factor: 5.258

7.  Visual outcome of secondary lens implantation after trauma or complicated retinal detachment surgery.

Authors:  H Mietz; W Konen; K Heimann
Journal:  Retina       Date:  1994       Impact factor: 4.256

8.  Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study.

Authors:  P S Hiscott; I Grierson; D McLeod
Journal:  Br J Ophthalmol       Date:  1984-10       Impact factor: 4.638

9.  Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy.

Authors:  P Wiedemann; C Leinung; R D Hilgers; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

10.  [Comparative immunohistochemical studies of epiretinal membranes in proliferative vitreoretinal diseases].

Authors:  H P Heidenkummer; A Kampik
Journal:  Fortschr Ophthalmol       Date:  1991
View more
  19 in total

1.  Deferred laser photocoagulation of relaxing retinotomies under silicone oil tamponade to reduce recurrent macular detachment in severe proliferative vitreoretinopathy.

Authors:  Marc Veckeneer; Kristel Maaijwee; David G Charteris; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-18       Impact factor: 3.117

2.  Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.

Authors:  Kaihui Nan; Feiyan Ma; Huiyuan Hou; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Acta Biomater       Date:  2014-05-02       Impact factor: 8.947

3.  A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.

Authors:  Huiyuan Hou; Kristyn Huffman; Sandy Rios; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

4.  Silicone assisted, argon laser confinement of recurrent proliferative vitreoretinopathy related retinal detachment: a technique to allow silicone oil removal in problem eyes.

Authors:  D H Steel; P Weir; C R James
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

5.  Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.

Authors:  B N M K Khanum; R Guha; V P Sur; S Nandi; S K Basak; A Konar; S Hazra
Journal:  Eye (Lond)       Date:  2017-03-17       Impact factor: 3.775

6.  Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Authors:  Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

7.  A novel function of p53: a gatekeeper of retinal detachment.

Authors:  Hetian Lei; Marc-Andre Rheaume; Jing Cui; Shizuo Mukai; David Maberley; Arif Samad; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

8.  Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.

Authors:  Kathrin I Hartmann; Alejandra Nieto; Elizabeth C Wu; William R Freeman; Jae Suk Kim; Jay Chhablani; Michael J Sailor; Lingyun Cheng
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-28       Impact factor: 2.671

9.  [Reasons and risk factors for recurrent retinal detachment after removal of silicon oil in various vitreoretinal diseases].

Authors:  Agharza Ashurov; Melanie Hundhammer; Walter Sekundo; Stephan Schulze
Journal:  Ophthalmologe       Date:  2021-06-04       Impact factor: 1.059

Review 10.  [Proliferative vitreoretinopathy process-To heal or not to heal].

Authors:  S Grisanti; S Priglinger; L Hattenbach
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.